Clinical Trials

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

450 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms

NCT03412877 2026-04-14

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

BreastEndocrineGynecologicNETPlasma cellThoracic

285 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT03786081 2026-04-14

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

Phase 1/2 Terminated

214 enrolled

Phase 1 Active not recruiting

Uterine Cervical Neoplasms

NCT02298959 2026-04-13

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

59 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicSarcoma

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

NCT03914612 2026-04-13

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Phase 3 Active not recruiting

813 enrolled 16 charts 2 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT05446298 2026-04-13

PRESERVE-004

58 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07198074 2026-04-13

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Phase 3 Recruiting

255 enrolled

Endometrial Neoplasms

NCT06253494 2026-04-09

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

60 enrolled

Endometrial Neoplasms

NCT06989112 2026-04-08

DE-01

Phase 3 Recruiting

600 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Neoplasms, Endometrial Neoplasms

NCT07262619 2026-04-08

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

160 enrolled

Turcot syndrome, Neoplasm Metastasis, Endometrial Neoplasms

NCT04389632 2026-04-07

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

1,006 enrolled

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT05579366 2026-04-07

RAINFOL-01

BreastGynecologicOther solid neoplasmThoracic

764 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Mesothelioma, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05920798 2026-04-06

FRAPPE

40 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03428802 2026-04-03

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

21 enrolled 9 charts

BreastGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT07290894 2026-04-02

MITO VULVA-01

80 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Vulvar Neoplasms

NCT04234113 2026-03-27

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

Phase 1 Terminated

115 enrolled 43 charts

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05036681 2026-03-27

A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma

Phase 2 Terminated

9 enrolled 10 charts

Neoplasm Metastasis, Endometrial Neoplasms

NCT06843447 2026-03-27

MK-5909-003

280 enrolled

Ovarian Cancer Recurrent

NCT04919629 2026-03-23

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

60 enrolled

Phase 1 Enrolling by invitation

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07218003 2026-03-23

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

149 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Esophageal Squamous Cell Carcinoma, Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT03517449 2026-03-19

MK-3475-775

Phase 3 Completed

827 enrolled 34 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT04430699 2026-03-19

Cisplatin+Pembrolizumab+RT in Vulvar Cancer

24 enrolled

Vulvar Neoplasms

NCT06036836 2026-03-19

MK-4280A-010

Phase 2 Completed

163 enrolled

DermatologicGenitourinaryGynecologicHead & NeckThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT06108479 2026-03-18

Study of DF6215 in Patients With Advanced Solid Tumors

Phase 1 Completed

35 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms

NCT04977453 2026-03-17

Keynote B59

317 enrolled

GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Neoplasm Metastasis

NCT05231122 2026-03-16

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

80 enrolled

BreastDermatologicGenitourinaryGynecologicHead & NeckThoracic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06894771 2026-03-16

MK-4700-001

Phase 1 Completed

5 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Melanoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06607185 2026-03-13

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Phase 1 Active not recruiting

750 enrolled

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT03239145 2026-03-12

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Phase 1 Completed

62 enrolled 17 charts

DermatologicGastrointestinalGenitourinaryGynecologic

Kidney Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

NCT04585750 2026-03-12

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

300 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gallbladder Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05269381 2026-03-12

PNeoVCA

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

132 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04712851 2026-03-10

Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

25 enrolled

BreastGastrointestinalGynecologicThoracic

Uterine Cervical Dysplasia

NCT04332653 2026-03-09

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Phase 1/2 Completed

215 enrolled 30 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Thoracic Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05116189 2026-03-09

KEYNOTE-B96

Phase 3 Active not recruiting

643 enrolled 17 charts 3 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07227168 2026-03-05

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

GastrointestinalGynecologic

200 enrolled

Uterine Cervical Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT01174121 2026-03-04

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

BreastGastrointestinalGynecologic

332 enrolled

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05467670 2026-03-04

Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer

16 enrolled

Ovarian Neoplasms

NCT06083844 2026-03-04

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

20 enrolled

Ovarian Neoplasms

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

134 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT05081609 2026-02-24

IL Believe

Phase 1/2 Active not recruiting

320 enrolled

Phase 1/2 Active not recruiting

Uterine Cervical Neoplasms, Neoplasm Metastasis

NCT05438420 2026-02-24

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

120 enrolled

GastrointestinalGynecologic

Uterine Cervical Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Stomach Neoplasms

NCT05603910 2026-02-24

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

18 enrolled

Endometrial Neoplasms

NCT05208762 2026-02-23

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

BreastGastrointestinalGynecologicHead & NeckThoracic

714 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04221945 2026-02-20

KEYNOTE-A18

Phase 3 Completed

1,060 enrolled 30 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

240 enrolled

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04752826 2026-02-18

MK-3475-D20